Type 2 & other diabetes

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c

Diabetes Obes MetabPublished Retrospective cohort study

Authors' conclusion

Real-world use of GLP-1RAs in youth with T2D is associated with decreased HbA1c levels, despite challenges with access and adherence. GLP-1RA treatment may reduce insulin doses for youth with T2D.

Study context

Population
Youth with T2D prescribed a GLP-1 RA at two academic paediatric diabetes centres before June 2022; median age 16.1 (IQR 13.9–18.0) years, 54% female, 56% non-Hispanic Black, 24% Hispanic, 77% public insurance
Participants
136 participants
Outcome
Change in HbA1c from baseline
Follow-up
First (median 91 days) and second (median 190 days)
Methodological detailsmulticentre, real-world
  • Multicentre
  • Real-world

Main finding

As reported in the abstract

Median HbA1c, baseline to first follow-up · median 91 days
GroupValueBaseline median HbA1c
GLP-1 RAmedian 7.6%7.9%

GLP-1 RA

Valuemedian 7.6%
Baseline median HbA1c7.9%
Median HbA1c decreased from 7.9% to 7.6%
P < 0.001

Observational data: associations, not effects.

Further findings

OutcomeValues
Median HbA1c, baseline to second follow-up · median 190 daysGLP-1 RA median 7.4% · baseline median HbA1c 8.4%
  • Median HbA1c, baseline to second follow-up: n = 83

Insulin prescribed, baseline to first follow-up

Basal insulin 69% to 60%
P = 0.008
Prandial insulin 46% to 38%
P = 0.03

HbA1c change per month (multivariable linear mixed effects model) · up to 6 months

Mean decrease in HbA1c per month
0.09 (percentage points; 95% CI −0.15, −0.03; P = .005)
  • Adjusted for sex, age, race/ethnicity, insurance, insulin regimen, metformin regimen, GLP-1 RA dosing frequency, BMI-Z

Original publication

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obes Metab. Published 16 January 2024. doi:10.1111/dom.15430

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.